Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis
-
Published:2024-09
Issue:
Volume:5
Page:100072
-
ISSN:2949-8198
-
Container-title:ESMO Gastrointestinal Oncology
-
language:en
-
Short-container-title:ESMO Gastrointestinal Oncology
Author:
Shimozaki K.ORCID, Fukuda K., Ooki A.ORCID, Nakayama I.ORCID, Yoshino K., Tamba M., Udagawa S., Fukuoka S., Osumi H., Wakatsuki T., Takahari D., Shinozaki E., Ogura M.ORCID, Chin K., Yamaguchi K.
Reference28 articles.
1. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial;Shitara;Lancet Oncol,2018 2. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017 3. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial;Hironaka;J Clin Oncol,2013 4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021 5. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
|
|